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COPD—Leading Cause of  
Death & Disability 
• US prevalence ~10-24 million (~6%)  
– ~10 million diagnosed (Chronic bronchitis >> emphysema) 
– ~14 million undiagnosed 
• 4th leading cause of death in US 
– ~120,000 deaths in 2000 
– In 2000, mortality in women surpassed men 
• Second leading cause of disability  
(after heart disease) 
• Frequent diagnosis in older population 
– Long latency period (~35 years) 
– Aging of US population 
– …Yet 70% younger than 65 
Mannino et al: MMWR 2002 
Mannino et al : Arch Int Med 2000 
AHRQ pub. 02-M016 
68 yo retired ER nurse wants help 
with dyspnea on exertion. Smoked 
1-2 ppd since starting in Army 
Nursing Corps late 1950s  
(>50 pk years).  
Which of the following statements 
are true? 
• Physical exam provided clues necessary to 
determine that she has COPD, you recommend 
inhalers 
• Chest x-ray is the best way to determine if 
COPD is the cause of her DOE. 
• Nearly all patients who smoke develop COPD. 
She probably has COPD & should be started on 
inhalers. 
How do you make diagnosis of COPD? 
What per cent of continuous smokers (> 25 pk yrs) 
develop COPD? 
• 25% = Absolute risk over 25 years of f/u (N=8045) 
• Most are mild to moderate severity 
Smoking history & Dyspnea does not automatically  COPD Dx 
Lokke A, et al.Copenhagen City Heart Study. Thorax 2006 
How do you make diagnosis of COPD? 
Are there diagnostic physical exam findings? 
What about Dahl’s Sign? 
There are no diagnostic physical findings which confirm COPD 
R = 0.57 
Reich SB et al. AJR 1984 
How do you make diagnosis of COPD? 
Is the CXR sensitive way to detect COPD? 
CXR seldom diagnostic, but valuable for excluding  
alternative dx & presence of comorbidities 
Which of the following statements 
are true? 
• Physical exam provided clues necessary to 
determine that she has COPD, you recommend 
inhalers 
• Chest x-ray is the best way to determine if 
COPD is the cause of her DOE. 
• Nearly all patients who smoke develop COPD. 
She probably has COPD & should be started on 
inhalers. 
NONE OF THESE! 
Spirometry Required to Diagnose COPD 
• Only ~33% newly diagnosed COPD have had 
spirometry… 
• 39% diagnosed as COPD by primary care 
provider, did not, upon checking spirometry… 
 
• ATS/ERS & GOLD Standards for diagnosis of 
COPD -> Spirometry 
Eur Heart J 2005 
Chest 2006; Chest 2007 
Eur Respir J 2004; GOLD 2013  
68 yo retired ER nurse wants help with 
dyspnea on exertion. Smoked 1-2 ppd since 
starting in Army Nursing Corps late 1950s  
(>50 pk years).  
Spirometry pre- & post-bronchodilator: 
• Moderate obstructive physiology 
• Significant improvement post-bronchodilator 
Based on these data you: 
- Explain to her she has COPD (not asthma) &  
- Reassure her that she should experience 
substantial improvement in dyspnea using the 
bronchodilators you will prescribe… 
Correct…? 
Incorrect…? 
Hanania NA. Chest 2011; 
Chest 2003  
COPD & FEV1 post Bronchodilator (BD) 
• Reversibility post BD (ATS) 
– 12% increase AND 
– 200 mL 
• Reversibility in COPD 
common (54-73%) 
• 150-200 mL  Threshold for 
perception of benefit 
• Data shows: 
– Reversible: max ~300 mL 
– Nonreversible: max ~150 mL 
– Health related QOL score same 
for reversible & nonreversible 
• Other BD studies show 
similar results (eg, tiotropium) 
Based on spirometry data you: 
- Explain to her she has COPD (not asthma)  
- Reassure her that she should experience 
substantial improvement in dyspnea using the 
bronchodilators you will prescribe… 
COPD & bronchodilator Rx:  
• Post BD spirometry response does not correlate with 
patient response to chronic bronchodilator Rx.  
• Magnitude of improvement small enough that 
substantial fraction of patients won’t recognize benefit 
• Neither reason should preclude bronchodilator 
therapeutic trial (1-3 months)  
• Post BD spirometry (reversibility) does not 
differentiate asthma from COPD 
 
 
Hanania NA. Chest 2011 
Bronchodilators in Chronic COPD 
Anti-cholinergics & 2 Agonists  
• Symptom management (prevent &/or reduce) 
• Long-acting bronchodilators  
– More convenient & effective compared to short acting 
– May reduce exacerbation frequency 
• No risk to using LABA alone (unlike asthma) 
• CV risk of tiotropium seems to be low/nil. 
• Short acting combination improves efficacy & reduces 
side effects compared to pushing dose of single Rx 
(Long acting combo data emerging) 
--GOLD 2013 
68 yo retired ER nurse wants help with 
dyspnea on exertion. Smoked 1-2 ppd since 
starting in Army Nursing Corps late 1950s  
(>50 pk years; FEV1 55%, DLCO 45%). 
Long acting inhaled BD & rescue albuterol MDI 
 Less dyspnea…  
…She wants more Rx to improve dyspnea.  
You recommend inhaled steroid reasoning that  
the root cause is chronic Inflammation (as w/ asthma) 
Correct? 
Incorrect? 
Peter J. Barnes, MD GOLD 2013 & 
National Heart and Lung Institute, London UK 
COPD Pharmacologic Rx 
Corticosteriod Data 
• Chronic inflammation of COPD not suppressed by 
inhaled or oral steroids  
(Culpitt SV et al AJRCCM 1999; Keatings et al AJRCCM 1997) 
• 10-20% chronic stable COPD pts show objective 
improvement 
– Probably have asthma also 
– Airway hyperresponsiveness predicts faster decline in FEV1 
(Tashkin DP et al AJRCCM 1996) 
• Long-term inhaled steroids do not effect progression of 
COPD (even started before patients symptomatic) 
(Pauwels RA et al NEJM 1999; Vestbo J et al Lancet 1999; Burge et al BMJ 2000)  
Steroids in Chronic COPD  
Inhaled Steroid Treatment 
• General rule: Chronic COPD resistant to steroid Rx 
• Up to 20% responsive (FEV1 improves) 
• Predicting inhaled steroid effect (asthma subgroup) 
– Acute PFT bronchodilator response-> No 
– Response during acute exacerbation-> No 
– Carefully monitored therapeutic trial-> Maybe 
• Decreases frequency of exacerbations 
GOLD C or D, 2 exacerbations/year  
• Combo Rx, Mod - Severe COPD, RDBPC trials… 
– Fluticasone-Salmeterol (500/50), N~4000 x 3 yrs: Small 
effect, better than either alone (TORCH, NEJM 2/07) 
– Tiotropium + Fluticasone-Salmeterol (500/50), N~450 x 1 yr: 
Small effect,  FEV1, Hospitalizations (UPLIFT, AIM 4/07) 
– Difficult studies to do/interpret…Attrition rate 40% 
COPD Recommendation: Inhaled Steroid 
Add to long acting inhaler(s):  
• Recurrent Exacerbations ( 2 exacerbations 
prior 12 months) 
• Concurrent Asthma  
• (Persistent symptoms) 
NB: ICS alone not recommended  
      Risk pneumonia 
      Risk osteopenia/fractures 
--GOLD 2013 
COPD: Combination Inhalers 
Budesonide/Formoterol MDI 80,160/4.5  2 puffs bid 
 
Mometasone/Formoterol MDI 200,400/5 MDI 2 puffs bid 
 
Fluticason/Salmeterol  
– MDI 45,115,230/21 2 puffs bid 
– DPI 100,250,500/50 1 puff bid 
 
Fluticasone/Vilanterol DPI 100/25 1 puff daily 
 
68 yo retired ER nurse wants help with 
dyspnea on exertion. Smoked 1-2 ppd since 
starting in Army Nursing Corps early 1960s  
 (>50 pk years; FEV1 55%, DLCO 45%). 
Long acting inhaled BD & rescue Albuterol MDI Less dyspnea  
…She wants more Rx to improve dyspnea.  
You recommend inhaled steroid reasoning that root cause of  
bronchospasm is chronic Inflammation (as w/ asthma)  
What could you do now? 
COPD: Hyperinflation, Air Trapping 
Beyond Bronchospasm to Explain Dyspnea 
Reduced expiratory flow rate due to compression, 
mucous, inflammation/edema  
• Increased time for exhalation required 
• Physiologic (PFT) changes: 
– Reduced FEV1 
– Increased Residual Volume (RV) &  
               Total Lung Capacity (TLC) 
Dynamic Hyperinflation 
Yawn & Keenan: COPD March 2007 
Mild COPDDynamic Hyperinflation  
Exercise Test: N = 21 w/ GOLD Stage I vs Control  
• Mean post BD FEV1 = 91% predicted 
• All w/ FEV1/FVC <70% 
• DLCO 98% predicted 
Results… 
• COPD: VO2 max 78% (nl 85%)  
• Control: VO2 max 101% 
• COPD group: Dynamic Hyperinflation 
Dynamic Hyperinflation Treatment  
• Patient recognition/comprehension 
– Not bronchospasm 
– Same amount of activity, but allow more time 
• Bronchodilators 
– Long acting -agonists & anti-cholinergics > Short acting 
• Pulmonary Rehab 
– Education (Comprehension, Pursed lip breathing) 
– Training Improved IC, Reduced RR for effort 
• Additive: Long acting bronchodilator Rx + Training 
Emtner et al: AJRCCM 2003; Ciro et al: AJRCCM 2005; 
Celli et al: Chest 2003; Casaburi et al: Chest 2005 
68 yo retired ER nurse wants help with 
dyspnea on exertion. Smoked 1-2 ppd since 
starting in Army Nursing Corps early 1960s  
 (>50 pk years; FEV1 55%, DLCO 45%). 
Long acting inhaled BD & rescue Albuterol MDI  
plus Exercise Less dyspnea, BUT…  
…She wonders if O2 will help her dyspnea.  
O2 Sat: Resting 95%; 6 min walk (6MWT) 85% 
Based on data which recommendation is correct: 
1. Continuous O2 24/7: Prevents heart failure & prolongs life OR 
2. O2 for exertion: Prevents heart failure & prolongs life OR 
3. O2 for exertion: Perhaps improves dyspnea & exercise OR 
4. O2 won’t help 
Jolly EC et al. Chest 2001 
Supplemental O2 May Improve Exercise 
Performance 
• Desaturators 
distance improved  
by 22% (P<0.02) 
• Dyspnea rating  in 
Desaturators & Non- 




Desaturators (N=10) vs Non-desaturators (N=10) 
DBPC 6MWT: O2 vs Compressed Air 
Nonoyama M et al. AJRCCM 2007 
Supplemental O2 May Improve Quality of Life 
• N=27 COPD, exertional desaturation (<88%) 
• “N-of-1 RCT” x3 (2 weeks) O2 vs RA 
• Only 2/27 showed consisted reduction in dyspnea 
Favors O2 
Favors RA 
68 yo retired ER nurse wants help with 
dyspnea on exertion. Smoked 1-2 ppd since 
starting in Army Nursing Corps early 1960s  
 (>50 pk years; FEV1 55%, DLCO 45%). 
Long acting inhaled BD & rescue Albuterol MDI  
plus Exercise  Less dyspnea, BUT…  
…She wonders if O2 will help her dyspnea.  
O2 Sat: Resting 95%; 6 min walk (6MWT) 85% 
Based on data which recommendation is correct: 
1. Continuous O2 24/7: Prevents heart failure & prolongs life OR 
2. O2 for exertion: Prevents heart failure & prolongs life OR 
3. O2 for exertion: Perhaps improves dyspnea & exercise OR 
4. O2 won’t help 
Data from 1980 : If resting O2 sat 88% (PO2 50), THEN 
Supplemental O2 >18 hr/day reduces mortality 
 Lancet 1981; AIM 1980 
Cumulative Benefits of Interventions 
Targeting Dyspnea 
--ATS Consensus Statement 1999 
Keep it realistic!! 
68 yo retired ER nurse wants help with 
dyspnea on exertion. Smoked 1-2 ppd since 
starting in Army Nursing Corps early 1960s  
 (>50 pk years; FEV1 55%, DLCO 45%). 
She needs Hip surgery which is planned 3 weeks hence. 
Which of the following regarding short-term pre-op 
smoking cessation is correct: 
1.Stop smoking now because it is a good idea 
2.Keep smoking until day of surgery, because 
complications are increased in those stopping over 
short term (<8 weeks pre-op) 
Warner MA et al: Anesthesiology 1984 
Pre-Op Smoking Cessation Dilemma 
• Smoking cessation both good and bad… 
– Short term quitters increases complications (57%) vs smokers (33%) 
– Nonsmokers & Quitters (>8 weeks)   complications (P <0.01) 
• Increased risk a/w short term smoking cessation pre-op persists 
in Textbooks, Consensus documents & subsequent studies 
since 1990, reflecting the power of “interpretive bias” 
Pre-op Smoking Cessation Paradox Refuted  
• Multiple studies past ~5 years demonstrate that 
pre-op smoking cessation does not 
paradoxically increase post-op complications 
 
• Anticipated surgery should be seen as a 
compelling teaching opportunity for stressing 
both short & long-term value of smoking 
cessation 
Theadom et al, Tob Control 2006; Myers et al Arch Int Med 2011 
Shi Y & Warner DO, Anesth 2010; Barrera et al Chest 2005 
68 yo retired ER nurse wants help with 
dyspnea on exertion. Smoked 1-2 ppd since 
starting in Army Nursing Corps early 1960s  
 (>50 pk years; FEV1 55%, DLCO 45%). 
During immediate post-operative period, she suffers NSTEMI  
The consult cardiologist recommends adding -blocker Rx 
Which of the following is correct: 
 
1. COPD is a relative contraindication for beta-blocker Rx 
 
2. Patients w/ COPD & CAD do better on beta-blocker Rx 
-Blocker-COPD Dogma…Revised 
Avoid -blockers in COPD pts d/t broncho-
constrictive property & competition w/ -agonist  
• Cardiovascular disease (eg, CAD, HTN, CHF) 
concurrent commonly (~50%) in COPD pts 
• Meta-analysis showed that cardio-selective beta-
blockers in mild-moderate COPD produced no 
negative effect on FEV1 & respiratory symptoms 
 
• Do COPD pts benefit w/ cardio-selective -blocker? 
Salpeter et al. Annals Int Med 2002 
Gottlieb et al: NEJM 1998; Rutten FH et al: Arch Int Med 2011  
-Blockers Reduce  
Mortality (post MI) & Risk of Exacerbations 
• Left Panel 40% reduction in 2 year post MI mortality in COPD 
attributable to -blocker Rx 
• Right Panel N=2230 COPD pt f/u x 7.2 yr, 30% -blocker Rx 
Beta blocker Rx reduced mortality & # acute exacerbations 
COPD Roses Among the Thorns… 
Conclusions 
• Perform Spirometry to diagnose COPD 
– Only 25% of smokers develop COPD 
– Physical exam (Pink Puffer/Blue Bloater/Dahls) & CXR too 
insensitive 
• Reversibility post bronchodilator does not… 
– Identify true asthmatic from COPD 
– Discern whether an individual with COPD will benefit from 
bronchodilator Rx… 
• Dynamic Hyperinflation causes dyspnea in many 
COPD patients (even mild). Improves with 
– Education & Exercise (Pulmonary Rehab) 
– Long acting inhalers 
 
COPD Roses Among the Thorns…Cont’d 
• Inhaled steroids beneficial when added to long acting 
inhalers 
–  2 exacerbations/year 
– Not necessarily d/t effect on airway inflammation 
• O2 supplementation benefits COPD w/ resting 
hypoxemia (SaO2<88%), but limited benefit in those 
w/ only exertion hypoxemia 
• Pre-op: Compelling teaching opportunity for stressing 
both short & long-term value of smoking cessation 
• Cardio-selective -blockers not only safe but may 
improve outcomes in COPD  
